167 related articles for article (PubMed ID: 10975605)
1. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
Aithal GP; Day CP; Leathart JB; Daly AK
Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605
[TBL] [Abstract][Full Text] [Related]
2. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes.
Yamazaki H; Inoue K; Chiba K; Ozawa N; Kawai T; Suzuki Y; Goldstein JA; Guengerich FP; Shimada T
Biochem Pharmacol; 1998 Jul; 56(2):243-51. PubMed ID: 9698079
[TBL] [Abstract][Full Text] [Related]
3. The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.
Yasar U; Eliasson E; Forslund-Bergengren C; Tybring G; Gadd M; Sjöqvist F; Dahl ML
Eur J Clin Pharmacol; 2001 Dec; 57(10):729-35. PubMed ID: 11829203
[TBL] [Abstract][Full Text] [Related]
4. In-vitro metabolism of celecoxib, a cyclooxygenase-2 inhibitor, by allelic variant forms of human liver microsomal cytochrome P450 2C9: correlation with CYP2C9 genotype and in-vivo pharmacokinetics.
Tang C; Shou M; Rushmore TH; Mei Q; Sandhu P; Woolf EJ; Rose MJ; Gelmann A; Greenberg HE; De Lepeleire I; Van Hecken A; De Schepper PJ; Ebel DL; Schwartz JI; Rodrigues AD
Pharmacogenetics; 2001 Apr; 11(3):223-35. PubMed ID: 11337938
[TBL] [Abstract][Full Text] [Related]
5. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase.
Crespi CL; Miller VP
Pharmacogenetics; 1997 Jun; 7(3):203-10. PubMed ID: 9241660
[TBL] [Abstract][Full Text] [Related]
6. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
Yamazaki H; Inoue K; Shimada T
Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
[TBL] [Abstract][Full Text] [Related]
7. The effect of genetic polymorphisms in CYP2C9 on sulphamethoxazole N-hydroxylation.
Gill HJ; Tjia JF; Kitteringham NR; Pirmohamed M; Back DJ; Park BK
Pharmacogenetics; 1999 Feb; 9(1):43-53. PubMed ID: 10208642
[TBL] [Abstract][Full Text] [Related]
8. [Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced influenza-virus-associated encephalopathy].
Funato T; Kozawa K; Kaku M
Rinsho Byori; 2002 Feb; 50(2):140-5. PubMed ID: 11925850
[TBL] [Abstract][Full Text] [Related]
9. Lack of differences in diclofenac (a substrate for CYP2C9) pharmacokinetics in healthy volunteers with respect to the single CYP2C9*3 allele.
Shimamoto J; Ieiri I; Urae A; Kimura M; Irie S; Kubota T; Chiba K; Ishizaki T; Otsubo K; Higuchi S
Eur J Clin Pharmacol; 2000 Apr; 56(1):65-8. PubMed ID: 10853880
[TBL] [Abstract][Full Text] [Related]
10. Is diclofenac a valuable CYP2C9 probe in humans?
Morin S; Loriot MA; Poirier JM; Tenneze L; Beaune PH; Funck-Brentano C; Jaillon P; Becquemont L
Eur J Clin Pharmacol; 2001; 56(11):793-7. PubMed ID: 11294368
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of warfarin elimination and its clinical implications.
Takahashi H; Echizen H
Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
[TBL] [Abstract][Full Text] [Related]
12. Role of CYP2C9 polymorphism in losartan oxidation.
Yasar U ; Tybring G; Hidestrand M; Oscarson M; Ingelman-Sundberg M; Dahl ML; Eliasson E
Drug Metab Dispos; 2001 Jul; 29(7):1051-6. PubMed ID: 11408373
[TBL] [Abstract][Full Text] [Related]
13. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.
Aithal GP; Day CP; Kesteven PJ; Daly AK
Lancet; 1999 Feb; 353(9154):717-9. PubMed ID: 10073515
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of diclofenac and inhibition of cyclooxygenases 1 and 2: no relationship to the CYP2C9 genetic polymorphism in humans.
Kirchheiner J; Meineke I; Steinbach N; Meisel C; Roots I; Brockmöller J
Br J Clin Pharmacol; 2003 Jan; 55(1):51-61. PubMed ID: 12534640
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates.
Takanashi K; Tainaka H; Kobayashi K; Yasumori T; Hosakawa M; Chiba K
Pharmacogenetics; 2000 Mar; 10(2):95-104. PubMed ID: 10761997
[TBL] [Abstract][Full Text] [Related]
16. Catalytic activity of three variants (Ile, Leu, and Thr) at amino acid residue 359 in human CYP2C9 gene and simultaneous detection using single-strand conformation polymorphism analysis.
Ieiri I; Tainaka H; Morita T; Hadama A; Mamiya K; Hayashibara M; Ninomiya H; Ohmori S; Kitada M; Tashiro N; Higuchi S; Otsubo K
Ther Drug Monit; 2000 Jun; 22(3):237-44. PubMed ID: 10850388
[TBL] [Abstract][Full Text] [Related]
17. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin: catalytic activities of cDNA-expressed CYP2C9, its Leu359 variant and their mixture versus unbound clearance in patients with the corresponding CYP2C9 genotypes.
Takahashi H; Kashima T; Nomoto S; Iwade K; Tainaka H; Shimizu T; Nomizo Y; Muramoto N; Kimura S; Echizen H
Pharmacogenetics; 1998 Oct; 8(5):365-73. PubMed ID: 9825828
[TBL] [Abstract][Full Text] [Related]
18. Allelic and functional variability of cytochrome P4502C9.
Bhasker CR; Miners JO; Coulter S; Birkett DJ
Pharmacogenetics; 1997 Feb; 7(1):51-8. PubMed ID: 9110362
[TBL] [Abstract][Full Text] [Related]
19. CYP2C9 polymorphisms and CYP2C9*2 genotyping primers.
Goldstein JA
Br J Clin Pharmacol; 2002 Apr; 53(4):409-10. PubMed ID: 11966681
[No Abstract] [Full Text] [Related]
20. Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans.
Shon JH; Yoon YR; Kim KA; Lim YC; Lee KJ; Park JY; Cha IJ; Flockhart DA; Shin JG
Pharmacogenetics; 2002 Mar; 12(2):111-9. PubMed ID: 11875365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
